Navigation Links
BioLineRx Reports Third Quarter 2013 Financial Results
Date:11/13/2013

JERUSALEM, Nov. 13, 2013 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, today reported its results for the third quarter ending September 30, 2013.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769)

Kinneret Savitsky, Ph.D., Chief Executive Officer of BioLineRx, stated, "As we approach the end of 2013, we see the Company's continued progress towards several significant catalysts over the next several quarters. For instance, one of our most advanced assets, BL-1040 for the prevention of ventricular remodeling post AMI, is progressing as scheduled at full steam in the PRESERVATION I CE-Mark registration trial. Fifty-five sites are currently open, including 14 in the U.S., and final results are expected in 2014."

Other highlights

BL-8040 (AML and other hematological indications):

  • Granted orphan drug designation by the FDA, allowing a faster clinical path toward commercialization 
  • Added Memorial Sloan Kettering Cancer Center in New York to join the Phase 2 multi-center study, bringing the total number of sites to eight
  • Received patent allowance through 2029 from the USPTO for method of obtaining stem cells
  • "During the third quarter, we made significant progress in our Phase 2 clinical trial for BL-8040, a best-in-class CXCR4 antagonist for the treatment of hematological cancers such as AML. In September, we received orphan drug status from the FDA, a designation with significant positive implications for BL-8040 as it advances through the clinic, including a seven-year market exclusivity period, clinical protocol assistance with the FDA, and federal grants and tax credits. We remain on track to deliver partial results from the trial by the end of this year, with final results expected in the se
    '/>"/>

    SOURCE BioLineRx Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
    2. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
    3. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
    4. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
    5. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
    6. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
    7. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
    8. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
    9. BioLineRx to Present at 15th International Celiac Disease Symposium
    10. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
    11. BioLineRx Appoints B. J. Bormann to Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... YORK , Oct. 22, 2014 Sanomedics ... August 2014 report by Global Research & Data Services, ... per year from 2014 through 2018, as demand for ... States is the world,s largest market for ... with advanced thermometers is Sanomedics International Holdings, Inc. ...
    (Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, Inc. ... results from the  IAP310 study have been published ... a peer-reviewed journal with broad, multidisciplinary readership. ... evaluating the safety and efficacy of Zalviso, also ... (SSTS), for the treatment of post-operative pain in ...
    (Date:10/20/2014)... MOUNTAIN VIEW, Calif. , Oct. 20, 2014 /PRNewswire/ ... field of interventional pulmonology, today announced completion of enrollment ... schedule.  The RENEW Clinical Study is the FDA-approved IDE ... treatment for severe emphysema. It was anticipated ... US in February 2013, would take until the end ...
    Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
    ... Inc. (OTC Bulletin Board: AEMD ), the ... disease and cancer, announced today that it has accepted ... Health and Human Services BARDA Industry Day on Wednesday, ... Broad Spectrum Antiviral Platform Technology" is scheduled to begin ...
    ... 14, 2010 /PRNewswire-Asia-FirstCall/ -- China Botanic Pharmaceutical Inc. ... the "Company"), a developer, manufacturer and distributor of ... today announced that as of fiscal year ending ... and nerve regulation product - Compound Schisandra Tablets ...
    Cached Medicine Technology:Aethlon Medical Announces Presentation at U.S. Department of Health and Human Services BARDA Industry Day 2Aethlon Medical Announces Presentation at U.S. Department of Health and Human Services BARDA Industry Day 3Aethlon Medical Announces Presentation at U.S. Department of Health and Human Services BARDA Industry Day 4China Botanic Achieves Three Million RMB Sales of New Product 2China Botanic Achieves Three Million RMB Sales of New Product 3
    (Date:10/22/2014)... 22, 2014 The Louis ... is dedicated to distribute health information technology innovation ... worldwide announced the development of six key guiding ... when receiving healthcare. These are an expansion of ... “providing care that is respectful of and responsive ...
    (Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
    (Date:10/22/2014)... Your Body’s Way , In a world where a multi-billion-dollar ... can be difficult to choose the right weight loss method. ... it the healthy way? Set aside the fads and resist ... regularly, and choose foods with the most nutritional benefits. ... exercise more and eat less. Despite the number of advertisements ...
    (Date:10/22/2014)... 22, 2014 Richard Carlson, Managing Partner ... leader with over 25 years experience. Mr. Carlson ... the areas related to EDI, B2B Commerce, RFID and ... Editorial Advisory Board member for Pharmaceutical Commerce Magazine and ... Fin Group is a management and technology consulting firm ...
    (Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
    Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
    ... New York, N.Y. February 7, 2008 Obesity ... the U.S. over the last two decades. A new ... characteristics of neighborhoods, including the areas income level, the ... the continuing obesity epidemic. , Researchers led by Jennifer ...
    ... say this way of checking estrogen-receptor status of participants ... News) -- In epidemiological studies of women with breast ... central laboratory testing for determining the estrogen-receptor status of ... reports is common practice in such studies, but it ...
    ... February 7, 2008 A seemingly random arterial ... in adults with no previous symptoms may not be ... the Netherlands discovered that many people with congenital aneurismal ... by identifying and treating patients at risk. They reported ...
    ... OAKLAND, Calif., Feb. 7 Nytera Tilmon works,at a ... her seven children,all of whom live with asthma. The ... television show revealing Nytera,s story and others,behind the healthcare ... Time" and it,s the only national labor-produced TV show., ...
    ... SINGAPORE, Feb. 7 Flextronics (Nasdaq: FLEX ... Power (FMP) business unit,of CEAG AG, a global ... telephones. FMP develops, produces and markets power supply ... sector.,FMP will become part of Flextronics,components business unit ...
    ... act as tumor suppressor, keeping bad cells in check ... called STAT3 acts like "Jekyll and Hyde" in glioblastoma brain ... researchers. , The finding may help improve treatment of people ... people in the prime of life and is almost always ...
    Cached Medicine News:Health News:Lower-income neighborhoods associated with higher obesity rates 2Health News:Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 2Health News:Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 3
    ... to its design, this is the ... stone therapy in urinary and biliary ... a multipurpose lithotripter with other applications ... nephrolithotomy. ,The basic system comprises the ...
    All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
    ... The Compact Sigma is designed to ... Quick, precise mechanical coupling eliminates clumsy ... be performed as well. Dorniers patented ... too. ,Positioning is simple using the ...
    The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
    Medicine Products: